The 6 linked references in paper I. Romanov S., E. Dronova L., E. Stanyakina Е., И. Романов С., Е. Дронова Л., Е. Станякина Е. (2019) “Диссеминированный медуллярный рак щитовидной железы. Оптимальный подход к лечению // Disseminated medullary thyroid carcinoma. Optimal approach to treatment” / spz:neicon:ogsh:y:2018:i:4:p:21-25

  1. Wells S. A. Jr, Asa S. L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567–610. DOI: 10.1089/thy. 2014.0335. PMID: 25810047.
  2. Sippel R. S., Kunnimalaiyaan M., Chen H. Current management of medullary thyroid cancer. Oncologist 2008;13 (5):539–47. DOI: 10.1634/theoncologist.2007-0239. PMID: 18515739.
  3. Roman S., Lin R., Sosa J. A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107(9):2134–42. DOI: 10.1002/cncr. 22244. PMID: 17019736.
  4. Valerio L., Pieruzzi L., Giani C. et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol) 2017;29(5):316–24. DOI: 10.1016/j.clon. 2017.02.009. PMID: 28318881.
  5. Wells S. A. Jr, Robinson B. G., Gagel R. F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134–41. DOI: 10.1200/JCO.2011.35.5040. PMID: 22025146.
  6. Maciel L. M. Z., Magalhães P. K. R. Medullary thyroid carcinoma – adverse events during systemic treatment: risk-benefit ratio. Arch Endocrinol Metab 2017;61(4):398–402. DOI: 10.1590/2359-3997000000267. PMID: 28658345. Вклад авторов